This article is more than 5 years old. Information may no longer be current.

VIDEO: Evidence mounts showing advantages of anti-VEGF therapy in proliferative diabetic retinopathy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WAIKOLOA, Hawaii — At Retina 2016, Michael S. Ip, MD, describes mounting evidence -- anecdotal data, secondary outcomes data and study results from the DRCR.net Protocol S study -- that anti-VEGF therapy is advantageous in patients with proliferative diabetic retinopathy.